(Reuters) - Johnson & Johnson reported lower-than-expected quarterly sales as a stronger dollar offset higher sales of the Band-Aid maker’s new drugs and older treatments.
The company’s international sales fell about 7 percent to $9.65 billion in the fourth quarter, accounting for about half of its total sales.
The dollar gained nearly 13 percent against a basket of major currencies in 2014, its strongest performance since 1997.
Revenue in J&J’s pharmaceuticals business rose 9.6 percent in the quarter, driven by higher sales of new drugs such as hepatitis C drug Olysio and older treatments such as psoriasis drug Stelara. The business accounts for about 44 percent of the company’s total sales.
However, sales in J&J’s medical devices business, its second largest, fell 9 percent.
The company’s net profit fell about 28 percent to $2.52 billion, or 89 cents per share, including a $1.1 billion charge related to its acquisition of Synthes Inc.
Excluding items, J&J earned $1.27 per share.
Total sales fell 0.6 percent to $18.25 billion.
Analysts on average had expected a profit of $1.26 per share and revenue of $18.55 billion, according to Thomson Reuters I/B/E/S.
J&J forecast a profit of $6.12-$6.27 per share for 2015.
Chief Financial Officer Dominic Caruso warned in October that a strong dollar could hurt the company’s 2015 earnings by 15-20 cents per share.
J&J’s shares were down 1 percent at $102.45 in premarket trading on Tuesday.
Reporting by Ransdell Pierson and Vidya L Nathan; Editing by Kirti Pandey